This is a preview of subscription content, log in via an institution to check access.
Notes
This study was funded by Boerhinger Ingelheim.
Reference
Ramos M, et al. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Effectiveness and Resource Allocation : 12 Aug 2021. Available from: URL: https://doi.org/10.1186/s12962-021-00299-z
Rights and permissions
About this article
Cite this article
Empagliflozin appears to be cost effective for T2DM patients with established CVD in China. PharmacoEcon Outcomes News 885, 8 (2021). https://doi.org/10.1007/s40274-021-07950-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-07950-x